

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hua Han Health Industry Holdings Limited

華瀚健康產業控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 587)

(1) UPDATE ON THE APPOINTMENT OF INDEPENDENT THIRD PARTY INVESTIGATOR; AND (2) SUSPENSION OF TRADING

Reference is made to (i) the announcement of Hua Han Health Industry Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 September 2016 in relation to the audit progress of the 2015/2016 Audit Work, the adjournment of the Board meeting, delay in publication of annual results of the Group for the year ended 30 June 2016 and suspension of trading in the shares and debt securities of the Company; (ii) the announcement of the Company dated 19 October 2016 in relation to the establishment of independent board committee; (iii) the announcement of the Company dated 21 November 2016 in relation to the appointment of an independent third party investigator (“**Investigator Announcement**”); (iv) the announcement of the Company dated 12 December 2016 in relation to the resumption conditions of the Company (“**Resumption Conditions Announcement**”); and (v) the announcement of the Company dated 16 December 2016 in relation to the proposed change of auditors (collectively, the “**Announcements**”). Unless the context otherwise requires, the capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

UPDATE ON THE APPOINTMENT OF INDEPENDENT THIRD PARTY INVESTIGATOR

As set out in the Investigator Announcement, the Independent Board Committee has engaged Grant Thornton to investigate the issues and matters referred to in the Letters. In view of the resumption condition (a) in the letter from the Stock Exchange dated 9 December 2016 as disclosed in the Resumption Conditions Announcement, the Board announces that the Independent Board Committee is in the course of liaising with Grant Thornton regarding the expansion of the scope of its investigation to cover the allegations as set out in the Emerson Reports.

The Company is now taking appropriate steps to fulfill the Resumption Conditions and will keep its shareholders and potential investors informed of the progress as and when appropriate.

SUSPENSION OF TRADING

At the request of the Company, trading in the Company's shares (stock code: 00587) and debt securities (stock code: 05676) have been suspended on The Stock Exchange of Hong Kong Limited with effect from 9:00 a.m. on Tuesday, 27 September 2016 and will remain suspended until further notice.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board of
Hua Han Health Industry Holdings Limited
Zhang Peter Y.
Chairman

Hong Kong, 7 February 2017

As at the date of this announcement, the Board comprises Mr. Zhang Peter Y., Mr. Deng Jie, Mr. Zhou Chong Ke, Mr. Chen Lei and Mr. Luo Zhan Biao as executive Directors, Mr. Tarn Sien Hao as non-executive Director, and Professor Lin Shu Guang, Professor Zhou Xin and Mr. Tso Sze Wai as independent non-executive Directors.